References
- O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain 2002; 18(6 Suppl): S182-90. https://doi.org/10.1097/00002508-200211001-00011
- Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28: 140-75. https://doi.org/10.1016/j.jpainsymman.2004.05.002
- Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005; 53: 3-9.
- Calderon-Gonzalez R, Calderon-Sepulveda RF. Clinical treatment (non surgical) of spasticity in cerebral palsy. Rev Neurol 2002; 34: 1-6.
- Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-2.
- Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044-9. https://doi.org/10.1016/S0161-6420(80)35127-0
- Truong DD, Stenner A, Reichel G. Current clinical applications of botulinum toxin. Curr Pharm Des 2009; 15: 3671-80. https://doi.org/10.2174/138161209789271843
- Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol 2009; 10: 87-102. https://doi.org/10.2165/00128071-200910020-00002
- Kharkar S, Ambady P, Yedatore V, Schwartzman RJ. Intramuscular botulinum toxin A (BtxA) in complex regional pain syndrome. Pain Physician 2011; 14: 311-6.
- Lim SJ, Park HJ, Lee SH, Moon DE. Ganglion impar block with botulinum toxin type a for chronic perineal pain -a case report-. Korean J Pain 2010; 23: 65-9. https://doi.org/10.3344/kjp.2010.23.1.65
- Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol 2003; 21: 476-80. https://doi.org/10.1016/j.clindermatol.2003.11.006
- Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65: 1423-9. https://doi.org/10.1212/01.wnl.0000183055.81056.5c
- Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 213-7.
- Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005; 20: 1152-60. https://doi.org/10.1002/mds.20531
- Callaway JE. Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol 2004; 22: 23-8.
- Akkaya T, Unlu E, Alptekin A, Gumus HI, Umay E, Cakci A. Neurolytic phenol blockade of the obturator nerve for severe adductor spasticity. Acta Anaesthesiol Scand 2010; 54: 79-85. https://doi.org/10.1111/j.1399-6576.2009.02130.x
- Al-Saleem FH, Ancharski DM, Ravichandran E, Joshi SG, Singh AK, Gong Y, et al. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J Pharmacol Exp Ther 2008; 326: 856-63. https://doi.org/10.1124/jpet.108.136242
- Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs 2002; 62: 705-22. https://doi.org/10.2165/00003495-200262040-00011
- Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg 2001; 20: 127-36. https://doi.org/10.1053/sder.2001.24421
- Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 2005; 37: 252-7. https://doi.org/10.1080/16501970510027312
Cited by
- Lumbar Sympathetic Block with Botulinum Toxin Type A and Type B for the Complex Regional Pain Syndrome vol.10, pp.4, 2018, https://doi.org/10.3390/toxins10040164
- Long-Term Clinical Outcomes of War-Related Hip Disarticulation and Transpelvic Amputation : vol.95, pp.16, 2011, https://doi.org/10.2106/jbjs.l.01160
- A Morphometric Study of the Obturator Nerve around the Obturator Foramen vol.59, pp.3, 2016, https://doi.org/10.3340/jkns.2016.59.3.282